Maheux R, Lemay A, Turcot-Lemay L
Research Center, St. François d'Assise Hospital, Quebec, Canada.
Am J Obstet Gynecol. 1988 Feb;158(2):361-4. doi: 10.1016/0002-9378(88)90155-x.
Twenty-six women with uterine leiomyoma were treated for 6 months with subcutaneous injections of the luteinizing hormone-releasing hormone agonist buserelin. Eight women received 200 micrograms daily, eight women received 350 micrograms daily, and 10 women after initial administration of 200 micrograms every 8 hours for 7 days, 500 micrograms of buserelin was administered daily. After 1, 3, and 6 months of treatment, serum luteinizing hormone levels were measured before and 4 and 8 hours after the administration of buserelin. The area under the curve for acute luteinizing-hormone response was then individually calculated. The inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment was proportional to the dosage used and remained constant during the treatment period.
26名患有子宫平滑肌瘤的女性接受了为期6个月的皮下注射促黄体生成激素释放激素激动剂布舍瑞林的治疗。8名女性每天接受200微克注射，8名女性每天接受350微克注射，10名女性在最初每8小时注射200微克，持续7天后，每天注射500微克布舍瑞林。在治疗1、3和6个月后，在注射布舍瑞林前以及注射后4小时和8小时测量血清促黄体生成激素水平。然后分别计算急性促黄体生成激素反应的曲线下面积。促黄体生成激素释放激素激动剂治疗期间急性促黄体生成激素反应的抑制与所用剂量成正比，且在治疗期间保持不变。
